4.7 Article

Mild ovarian stimulation for IVF: 10 years later

Journal

HUMAN REPRODUCTION
Volume 25, Issue 11, Pages 2678-2684

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/humrep/deq247

Keywords

mild ovarian stimulation; IVF; GnRH antagonist; infertility; FSH

Funding

  1. Andromed
  2. Ardana
  3. Ferring
  4. Genovum
  5. Glycotope
  6. Merck Serono
  7. Organon
  8. Pantharei Bioscience
  9. Philips
  10. PregLem
  11. Schering
  12. Schering Plough
  13. Serono
  14. Wyeth
  15. IBSA
  16. Organon Schering Plough
  17. Ipsen

Ask authors/readers for more resources

Ovarian stimulation to achieve multiple follicle development has been an integral part of IVF treatment. In the context of improved laboratory performance, the need for a large number of oocytes as an integral part of a successful IVF programme may be questioned. The aim of the current debate is to summarize the studies performed during the last decade to develop the concept of mild stimulation aiming to obtain fewer than eight oocytes. Here we examine the balance between IVF success and patient discomfort, and complications and cost, and how these might improve by simpler ovarian stimulation protocols aimed at retrieving fewer oocytes. We intend to analyse why progress has been rather slow and why there is much resistance to mild stimulation. Finally, presumed useful directions for future research will be discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available